Humacyte, Inc. (HUMA)
Total Valuation
Humacyte has a market cap or net worth of $359.11 million. The enterprise value is $315.91 million.
Market Cap | 359.11M |
Enterprise Value | 315.91M |
Important Dates
The last earnings date was Friday, March 22, 2024, before market open.
Earnings Date | Mar 22, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Humacyte has 116.98 million shares outstanding. The number of shares has increased by 0.40% in one year.
Shares Outstanding | 116.98M |
Shares Change (YoY) | +0.40% |
Shares Change (QoQ) | +0.08% |
Owned by Insiders (%) | 32.03% |
Owned by Institutions (%) | 15.54% |
Float | 71.00M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | 525.68 |
PB Ratio | 9.71 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.80, with a Debt / Equity ratio of 1.53.
Current Ratio | 6.80 |
Quick Ratio | n/a |
Debt / Equity | 1.53 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -12.73 |
Financial Efficiency
Return on equity (ROE) is -120.40% and return on invested capital (ROIC) is -100.94%.
Return on Equity (ROE) | -120.40% |
Return on Assets (ROA) | -50.70% |
Return on Capital (ROIC) | -100.94% |
Revenue Per Employee | n/a |
Profits Per Employee | -$545,061 |
Employee Count | 164 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.32% in the last 52 weeks. The beta is 1.52, so Humacyte's price volatility has been higher than the market average.
Beta (1Y) | 1.52 |
52-Week Price Change | -4.32% |
50-Day Moving Average | 3.50 |
200-Day Moving Average | 3.08 |
Relative Strength Index (RSI) | 41.56 |
Average Volume (30 Days) | 906,301 |
Short Selling Information
The latest short interest is 3.78 million, so 3.23% of the outstanding shares have been sold short.
Short Interest | 3.78M |
Short Previous Month | 5.95M |
Short % of Shares Out | 3.23% |
Short % of Float | 5.33% |
Short Ratio (days to cover) | 6.60 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -94.66M |
Pretax Income | -89.39M |
Net Income | -89.39M |
EBITDA | -74.83M |
EBIT | -82.88M |
Earnings Per Share (EPS) | -$0.87 |
Balance Sheet
The company has $99.99 million in cash and $56.78 million in debt, giving a net cash position of $43.21 million or $0.37 per share.
Cash & Cash Equivalents | 99.99M |
Total Debt | 56.78M |
Net Cash | 43.21M |
Net Cash Per Share | $0.37 |
Equity / Book Value | 36.99M |
Book Value Per Share | 0.32 |
Working Capital | 87.71M |
Cash Flow
In the last 12 months, operating cash flow was -$73.21 million and capital expenditures -$2.81 million, giving a free cash flow of -$76.02 million.
Operating Cash Flow | -73.21M |
Capital Expenditures | -2.81M |
Free Cash Flow | -76.02M |
FCF Per Share | -$0.74 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Humacyte does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.40% |
Shareholder Yield | -0.40% |
Earnings Yield | -24.89% |
FCF Yield | -21.17% |
Analyst Forecast
The average price target for Humacyte is $7.00, which is 125.81% higher than the current price. The consensus rating is "Buy".
Price Target | $7.00 |
Price Target Difference | 125.81% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | 149.00% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |